Alopecia

Sun Pharmaceuticals has launched deuruxolitinib (Leqselvi) in the US, offering a new treatment for adults with severe alopecia areata.

A systematic review reveals critical diagnostic gaps in hair loss treatment for patients with skin of color, urging improved training and protocols in dermatology.

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

From JAK inhibitors to trichoscopy and contact allergy clues, experts at SDPA 2025 shared their top clinical pearls for managing alopecia and hair loss.

Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail.

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

PP405 shows promise for hair regrowth in phase 2a trial, with 31% seeing >20% density increase; phase 3 studies are planned for 2026.

Subgroups more likely to respond included women and those with shorter-duration, less-extensive hair loss.

In a real-world study, the combination of Cuticapil stem hair serum and minoxidil reduced shedding and improved hair density.

Explore the significant mental health and socioeconomic impacts of atopic dermatitis and alopecia areata, revealing urgent needs for better support and awareness.

A 10-year study reveals azathioprine's impressive 93% hair regrowth rate in patients with moderate to severe alopecia, highlighting its long-term efficacy and safety.

In a new study, AI-driven personalized treatments significantly enhanced hair growth and scalp health, offering innovative solutions for hair loss management.

Significant unmet needs were found among high-quality validation studies on the internal structure of PROMs specific to alopecia areata.

A novel electrotrichogenic device shows promising results in promoting dense, thickened hair growth for male androgenetic alopecia patients.

The developement of bempikibart offers hope for effective treatment of severe alopecia areata amid unmet medical needs.

The innovative 21-item Hair & Scalp CARE questionnaire is designed to evaluate the psychological impact of hair and scalp conditions on quality of life.

JAK inhibitors show promise in treating alopecia areata among Black patients, highlighting the need for inclusive clinical research and equitable access to therapies.

A recent meta-analysis evaluates the efficacy and safety of various JAK inhibitors for alopecia areata, highlighting 12 mg twice daily deuruxolitinib as the most effective treatment.

At week 24, the proportion of Asian patients achieving significant hair regrowth (SALT ≤20) was substantially higher in ritlecitinib treatment groups than in placebo groups.

According to a clinical trial and in vitro study, TTFE can promote scalp health and hair growth by 96.88% while reducing inflammation.

An expert discusses a comprehensive review of treatment options for a 32-year-old woman with alopecia areata, covering baricitinib dosing (4 mg initially), monitoring requirements vs ritlecitinib, expected outcomes, and considerations for topical immunotherapy vs JAK inhibitors.

An expert discusses a 32-year-old woman with alopecia areata affecting eyebrows/eyelashes. Treatment options include topical/intralesional steroids, minoxidil, prostaglandin analogues, JAK inhibitors, and cosmetic approaches.

An expert discusses how alopecia areata significantly affects adolescent mental health. Treatment with ritlecitinib requires proper severity assessment via Severity of Alopecia Tool (SALT) score, clear communication of realistic timelines and goals, careful monitoring, and discussion of potential adverse effects. Long-term adherence is crucial for maintaining results.

An expert discusses how treatment for this adolescent boy with severe alopecia areata must balance efficacy with age-appropriate safety, considering psychological impact, growth/development factors, and family preferences while selecting among topical, intralesional, systemic, or emerging biologic options.